in this study A clinical study to evaluate the effectiveness of Virechana followed by Vardhamana Pippali Rasayana in managing COPD (Tamaka Swasa) and assessing Desmosine levels as a lung degradation biomarker.

A single-arm Clinical Study to evaluate the effectiveness of Virechana followed by Vardhamana Pippali Rasayana in the management of COPD (Tamaka swasa) along with assessing Desmosine level - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096387

Enrollment

Registered

2025-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Individuals aged between 25 and 60 years. Diagnosed with Tamaka Swasa based on Clinical signs and symptoms like Swasakrichata,kasa,urashoola,ghurghurkam shabada,peenasa,anidra, etc. Classified with mild to moderate COPD according to GOLD criteria. FEV1/FVC ratio is less than 0.70 postbronchodilator, and FEV1 ranges from 50% to 80% of the predicted value. Willing and able to undergo Virechana Karma and Vardhamana Pippali Rasayana. Provided a written informed consent. asthma

Exclusion criteria

Exclusion criteria: Severe or very severe COPD (FEV1 below 50% of predicted) or an acute exacerbation in the last 4 weeks. FEV1/FVC ratio exceeding 0.70 (indicating a non-obstructive pattern).. Severe respiratory distress requiring emergency care, known case of Lung cancer, bronchiectasis, interstitial lung disease, Congenital heart disease, uncontrolled Diabetes mellitus, pneumonia, lung fibrosis, HTN, pneumothorax, and tuberculosis. Women who are pregnant or breastfeeding Individuals who are unfit for Virechana karma and Vardhamana pippali rasayana Patient taking steroid therapy (systemic or inhaled corticosteroid)

Design outcomes

Secondary

Measure	Time frame
Changes in urine desmosine level Improvement in quality of life (SF-36) Changes in CAT Questionnaire score, Mmrc Dyspnea scale, and BODE Index Timepoint: Urine desmosine-baseline, AT Subjective parameters: baseline, AT, AF	—

Primary

Measure	Time frame
Changes in clinical presentation along with lung function tests (FEV1/FVC, FEV1%, PEFR)Timepoint: Baseline, AT, AF	—

Countries

India

Contacts

Public ContactDrPraveen kumar KS

All india institute of Ayurveda,Delhi

dr.ananthramsharma@gmail.com9495130595

Outcome results